Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Ovarian cancer is a gynecological cancer that has the highest mortality rate and is often resistant to conventional treatments. Therefore, development of new therapies is essential. Metformin (MET), which is the priority drug for treatment of type 2 diabetes, has received increasing attention because of its anti-tumor effects. Here, we examined combined anti-tumor effects of MET and RG7388, the only MDM2 (mouse double minute 2 homolog) antagonist that has entered phase III clinical trials, on ovarian cancer cell lines. We examined effects on proliferation by Cell Counting Kit-8 (CCK-8) and colony formation assays, and effects on apoptosis by flow cytometric analysis and Hoechst staining. Western blotting was used to measure protein expression in cells and tissues treated with MET and/or RG7388. Flow cytometry was used to measure reactive oxygen species (ROS). We also examined the effects of MET and/or RG7388 on inhibition of A2780 cell growth in vivo. The combination of MET and RG7388 significantly increased growth inhibition, apoptosis, and ROS of A2780 and SKOV3 cells compared with either agent alone. Additionally, in vitro and in vivo results showed that MET and/or RG7388 inhibited the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and their combination had a stronger effect. Our findings suggest that the combination of MET and RG7388 enhances growth inhibition and apoptosis induction of ovarian cancer cells through the PI3K/AKT/mTOR pathway and accumulation of intracellular ROS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RG7388 activates p53 to inhibit hematological tumors345 and solid tumors,346,347 but long-term administration may lead to p53 mutations and drug resistance.348,349”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [347]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release
Zorov, D. B., Juhaszova, M., & Sollott, S. J. (2014) · Physiological Reviews · doi:10.1152/physrev.00026.2013 · Cited by 5,383
Reactive oxygen species in cancer
Liou, G.-Y., & Storz, P. (2010) · Free Radical Research · doi:10.3109/10715761003667554 · Cited by 3,382
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Reactive Oxygen Species in the Tumor Microenvironment: An Overview
Weinberg, F., Ramnath, N., & Nagrath, D. (2019) · Cancers · doi:10.3390/cancers11081191 · Cited by 502
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Metformin reduces endogenous reactive oxygen species and associated DNA damage
Algire, C., Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., & Pollak, M. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0536 · Cited by 372
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Hong, B., Heuvel, A., Prabhu, V., Zhang, S., & El-Deiry, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition
Roy, R., Singh, S. K., Chauhan, L. K. S., Das, M., Tripathi, A., & Dwivedi, P. D. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.02.024 · Cited by 215
Metformin – its potential anti-cancer and anti-aging effects
Podhorecka, M., Ibanez, B., & Dmoszyńska, A. (2017) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0010.3801 · Cited by 203
Research works printed but not linked: 8
- Siegel, 2020, Cancer statistics, 70, 7
- Lheureux, 2019, Epithelial ovarian cancer: Evolution of management in the era of precision medicine, 69, 280
- Li, 2018, Metformin use and its effect on gastric cancer in patients with type 2 diabetes: a systematic review of observational studies, Oncol Lett, 15, 1191
- Yang, 2019, Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents, Oncol Lett, 18, 2404
- Lim, 2016, Targeted therapy in ovarian cancer, Women’s Health, 12, 363
- Cheaib, 2015, The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges, Chin. J. Canc., 34, 4
- Fu, 2017, Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway, Eur. Rev. Med. Pharmacol. Sci., 21, 1169
- Zheng, 2018, Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity, Am J Transl Res, 10, 3086
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer
Yao, K., Zheng, H., & Li, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942380 · Cited by 18
Metadata
- Authors
- Cui, Y., Zhou, J., & Rong, F.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 533
- Issue
- 4
- Pages
- 665-671
- ISSN
- 0006-291X
- Cited by
- 14
- References
- 27
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Technology Development Project of Shandong Medical and Health Science (2017WS280)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway. https://app.cochat.ai/papers/10.1016/j.bbrc.2020.09.135
- The paper
- Cui, Y., Zhou, J., & Rong, F. (2020). Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2020.09.135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.